At the news
? NEUTRALIMPACT 3/10 424B5 filed Nov 9, 2026 at 16:05 ET
Zimmer Biomet is issuing EUR 500 million of 4.375% notes due 2033, with net proceeds of approximately EUR 496.4 million (about $556.9 million) to be used for general corporate purposes including potential repayment of near-term maturing debt (EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027). The offering is a debt refinancing and capital management move, announced alongside a concurrent $500M USD notes offering. The company reported Q3 2026 results five days prior with modest revenue growth and raised full-year guidance.
- EUR 500,000,000 aggregate principal amount of 4.375% notes due November 12, 2033
- Net proceeds to issuer approximately EUR 496.4 million (about $556.9 million at EUR/USD 1.1219)
- Use of proceeds includes general corporate purposes, potential repayment of EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027, share repurchases, and acquisitions
- Concurrent offering of $500M 5.850% notes due 2036 announced; neither offering conditioned on the other
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access